Scholars Central

Short communicationPublished 2017

Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced Non-small Cell Lung Cancer

Authors: Erik DHondt

Immunotherapy: Open Access

Volume 3 · Issue 1 · Pages 1–2

More from this journal

The newest in Immunotherapy: Open Access.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalImmunotherapy: Open Access
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Erik DHondt”